Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Asset Writedowns and Impairment (2023 - 2024)

Senti Biosciences (SNTI) has 1 years of Asset Writedowns and Impairment data on record, last reported at $262000.0 in Q4 2023.

  • For Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $262000.0; the TTM value through Dec 2024 reached $26.0 million, changed N/A, while the annual FY2024 figure was $313000.0, 98.79% down from the prior year.
  • Asset Writedowns and Impairment reached $262000.0 in Q4 2023 per SNTI's latest filing, down from $25.7 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $25.7 million in Q3 2023 and bottomed at $262000.0 in Q4 2023.